pirfenidone has been researched along with Cardiomyopathies, Primary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kossen, K; Pan, L; Ruhrmund, DW; Schaefer, CJ; Seiwert, SD | 1 |
| Hoey, AJ; Irwin, NG; Van Erp, C | 1 |
1 review(s) available for pirfenidone and Cardiomyopathies, Primary
| Article | Year |
|---|---|
Antifibrotic activities of pirfenidone in animal models.
Topics: Administration, Oral; Animals; Cardiomyopathies; Disease Models, Animal; Extracellular Matrix Proteins; Humans; Kidney Diseases; Liver Cirrhosis; Pulmonary Fibrosis; Pyridones; Signal Transduction; Transforming Growth Factor beta | 2011 |
1 other study(ies) available for pirfenidone and Cardiomyopathies, Primary
| Article | Year |
|---|---|
Long-term administration of pirfenidone improves cardiac function in mdx mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiomyopathies; Disease Models, Animal; Fibrosis; Male; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscular Dystrophy, Animal; Muscular Dystrophy, Duchenne; Myocardium; Pyridones; RNA, Messenger; Transforming Growth Factor beta; Ventricular Dysfunction, Left | 2006 |